Study Title

Phase II Trial of Radium-223 in Biochemically Recurrent Prostate Cancer

Study Details

Description:

Some men who have been treated for localized prostate cancer with surgery or radiation still show signs of the disease in their blood. This is called biochemically recurrent prostate cancer. Radium-223 is a small molecule. It uses radiation to kill cancer cells and improves survival in advanced prostate cancer. Researchers want to see if it can treat prostate cancer and induced immune changes earlier in the disease when the cancer is only detectable by prostate specific antigen (PSA) in the blood.

Sponsor:

National Cancer Institute

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468